- Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012
- The Breakthrough Designation is granted to the drug candidates as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available therapies for the disease
- PharmaShots has compiled a list of 41 therapies that have granted BTD by the US FDA in 2020
Date: Jan 30, 2020
Product: APR-246
- The US FDA has granted BTD for APR-246 in combination with azacitidine to treat myelodysplastic syndromes (MDS) with a susceptible TP53 mutation
- The BTD supports the development program for APR-246. The company continued its interaction with FDA regarding ongoing P-III study and clinical development program to advance APR-246
- APR-246 is a small molecule that has demonstrated reactivation of mutant and inactivated p53 protein by restoring wild-type p53 conformation and function and thereby inducing programmed cell death in human cancer cells
Resverlogix Received the US FDA Breakthrough Therapy Designation for Apabetalone
Date: Feb 03, 2020
Product: Apabetalone
- The US FDA has granted BTD for apabetalone in combination with SOC including high-intensity statins, for the secondary prevention of MACE in patients with T2D Mellitus and recent acute coronary syndrome
- In 2019, Resverlogix reported results of P-III BETonMACE that showed a reduction in hospitalizations due to CHF as well as improving CV outcomes in two pre-specified subpopulations including those with CKD
- Apabetalone is a first-in-class, BET inhibitor selective for the second bromodomain (BD2) within the BET proteins
Date: Feb 20, 2020
Product: Padcev + Keytruda
- The BT designation is based on P-Ib/II EV-103 study assessing Padcev + Keytruda (pembrolizumab) in patients with LA/ mUC who are unable to receive cisplatin-based CT treated in the 1L setting
- The FDA’s BT designation expedite the development and review of drugs that are intended to treat a serious or life-threatening condition
- Padcev is an ADC targeting Nectin 4 and has received the US FDA’s approval in Dec’2019, indicated for LA/mUC in patients prior treated with PD-1/PD-L1 and platinum-containing CT before & after surgery
Date: Feb 24, 2020
Product: Exebacase
- The BTD is based on P-II superiority trial assessing Exebacase + SOC antibiotic therapy vs SOC alone in patients with Staphylococcus aureus bacteremia, including endocarditis
- In a pre-specified analysis of the subgroup with MRSA infections, the clinical responder rate @day14 (74.1% vs 31.3%). The Exebacase demonstrated a reduction in the 30-day all-cause mortality, 4days reduction in length of hospital stay, and reductions in 30-day hospital readmission rates in MRSA-infected patients
- Exebacase is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus
Date: Feb 27, 2020
Product: Debio 1143
- The BTD is based on P-II results that demonstrated improvement of the 1EPs locoregional control rate @18mos. after CRT (21% improvement vs. control arm) and a marked PFS benefit vs the CRT + PBO arm after a 2-year follow-up period
- The BTD reaffirms that Debio 1143 has the potential to offer benefit over the current SOC in LA-SCCHN, responding to the high unmet need in this debilitating cancer type
- Debio 1143 is a potential first-in-class oral antagonist of IAPs, sensitizes tumor cells to radio-CT by promoting programmed cell death and fostering anti-tumor immunity
Date: Mar 03, 2020
Product: Esbriet (pirfenidone)
- The US FDA’s BT designation is based on P-II study assessing Esbriet vs PBO in patients aged ≥18-85yrs. with progressive fibrosing uILD, an FVC of ≥45%, DLco of ≥30%, >10% fibrosis on high-resolution CT and a high-resolution CT from the previous 12mos.
- The P-II study results: slowed disease progression; predicted median change in FVC measured by home spirometry (-87.7 vs -157.1 ml) @24wks.; DLco and 6MWD trended in favor of Esbriet; safety & tolerability profile is comparable with P-III studies in IPF
- Esbriet is an oral therapy, indicated to treat IPF and has received EMA & the FDA’s approval for the treatment of mild to moderate IPF in 2011 & 2014 respectively
Date: Mar 11, 2020
Product: JNJ-6372
- The FDA’s BT designation is based on a P-I study assessing the safety, efficacy & PK of JNJ-6372 as monothx. or in combination with lazertinib in patients with advanced NSCLC with EGFR Exon 20 insertion mutations, having disease progression on or after platinum-based CT
- The study aims to determine the recommended P-II dose in patients with advanced NSCLC. The enrollment of patients is ongoing into part 2 dose expansion cohorts to assess JNJ-6372 as monothx. in multiple NSCLC sub-populations with genomic alteration
- JNJ-6372 is an EGFR-MET bispecific Ab that targets activating and resistant EGFR and MET mutations and amplifications. The development of Ab followed the Janssen’s licensing agreement with Genmab for its DuoBody technology platform
Date: Mar 16, 2020
Product: Olumiant (baricitinib)
- The FDA’s BT designation is based on P-II results of P-II/III BRAVE-AA1 study assessing baricitinib vs PBO in patients with AA
- The P-II portion of the BRAVE-AA1 study demonstrated no new safety signals with no SAEs @36wks. Additionally, P-III portion of BRAVE-AA1 & P-III BRAVE-AA2 study, are currently evaluating baricitinib (2mg/4mg) vs PBO in patients with AA
- Olumiant is an approved treatment for adults with moderately to severely active RA, approved in ~65+ countries, including the US, member states of the EU and Japan
Date: Apr 08, 2020
Product: Sotatercept
- The US FDA has granted BTD to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH)
- Earlier, the company reported results of the P-II PULSAR study that demonstrated sotatercept has the potential to shift the current treatment paradigm and provide benefits to patients with PAH on top of currently available therapies
- Sotatercept is an investigational agent designed to be a selective ligand trap for members of the TGF-beta superfamily to rebalance BMPR-II signaling
Date: Apr 09, 2020
Product: Bavencio (avelumab)
- The companies have completed the submission of sBLA to the US FDA as 1L maintenance therapy for patients with LA/m-UC and have received FDA’s BT designation for the same indication. The sBLA is being reviewed under the FDA’s RTOR pilot program
- The sBLA is based on P-III JAVELIN Bladder 100 study assessing Bavencio + BSC vs BSC as monothx. in 700 patients with UC with no disease progression after platinum-based induction CT
- The study resulted in meeting 1EPs of OS in each of the co-primary populations of all randomized patients and patients with PD-L1-positive tumors. Bavencio is a PD-L1 antibody, acts by blocking the interaction of PD-L1 with PD-1 receptors
Date: Apr 28, 2020
Product: Mobocertinib (TAK-788)
- The BT designation is based on P-I/II study assessing the safety and efficacy of mobocertinib (160mg, qd) in patients with LA/ m NSCLC, harboring EGFR exon 20 insertion mutations, prior treated with systemic CT
- The P-I/II ongoing study results: mPFS (7.3mos.); ORR (43%); safety profile was manageable. The mobocertinib development program began in the NSCLC population and is expected to expand to additional underserved populations in other tumor types
- Mobocertinib is a potent, small-molecule TKI, designed to selectively target EGFR and HER2 exon 20 insertion mutations and has received the US FDA’s ODD in 2019
Date: May 18, 2020
Product: Enhertu (fam-trastuzumab deruxtecan-nxki)
- The US FDA’s BT designation is based on an ongoing P-II DESTINY-Lung01 study assessing Enhertu in 170 patients with HER2 mutant or HER2 overexpressing unresectable and m-nsq. NSCLC, progressed after one or more systemic therapies including CT, molecular targeted therapy or immunotherapy and data from P-I study, published in Cancer Discovery
- The overall safety and tolerability profile of Enhertu in the ongoing DESTINY-Lung01 study is consistent with the P-I study. This designation marks the third BT designation for Enhertu in the US and the fourth expedited regulatory designation received globally
- Enhertu is a HER2 directed ADC, received accelerated approval in the US & approval in Japan under the conditional early approval system for unresectable/ metastatic HER2 positive metastatic BC, prior treated with anti-HER2 based regimens
Date: Jun 08, 2020
Product: Brensocatib
- The BTD is based on P-II WILLOW study assessing brensocatib vs PBO in adults with NCFBE for reducing exacerbations
- Insmed expects to initiate a P-III program for brensocatib in bronchiectasis in the H2’21
- Brensocatib is a novel oral, reversible DPP1 inhibitor, currently being developed for the treatment of bronchiectasis and other inflammatory diseases
Date: Jun 26, 2020
Product: AXS-05
- The US FDA has granted the BTD for AXS-05 to treat AD agitation. The designation offers potential for expedited development and review
- The designation was based on P-II/III ADVANCE-1 study assessing AXS-05, bupropion vs PBO in 366 patients with AD. The study demonstrated substantial improvement in agitation; mean reduction from baseline in the CMAI total score @5wks. (15.4 vs 11.5 points); superior to bupropion on the CMAI total score and was well tolerated
- AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity has now received two BTD for separate CNS indications
Telix Received the US FDA’s Breakthrough Therapy Designation for TLX250-CDx (89Zr-girentuximab)
Date: Jul 01, 2020
Product: TLX250-CDx (89Zr-girentuximab)
- The US FDA has granted BTD for Telix’s renal cancer imaging product TLX250-CDx (89Zr-girentuximab)
- Under BTD, the FDA will work closely with Telix to provide guidance on the development of TLX250-CDx for the diagnosis of “indeterminate renal masses” that have been identified on CT or MRI imaging
- TLX250-CDx is being developed for the purpose of determining “indeterminate renal masses” are either ccRCC or non-ccRCC, using PET imaging
Date: Jul 06, 2020
Product: ER-004
- The BT designation is provided on three results from three XLHED subjects with a course of ER-004 intra-amniotic injections during the third trimester of pregnancy while the results were published in NEJM and showed profound and life-changing effects on infants
- The US FDA’s BT designation is granted to expedite the development and review of drugs for serious or life-threatening conditions allowing the program to benefit from all the FDA’s fast-track program feature
- In H2’21, EspeRare to enroll patients for the study which is also benefited with Fast Track and ODD and has also received the EMA’s PRIME designation and ODD
Concert’s CTP-543 Received the US FDA’s Breakthrough Therapy Designation to Treat Alopecia Areata
Date: Jul 08, 2020
Product: CTP-543
- The BTD is based on a P-II study assessing CTP-543 (4/8/12mg, bid) vs PBO in 149 patients with moderate-to-severe alopecia areata
- Results: 8 & 12mg doses of CTP-543 met its 1EPs with differences in the percentage of patients achieving a ≥ 50% relative change from baseline @24wks. as measured by SALT. Therapy was well-tolerated and showed significant hair regrowth
- CTP-543 is a JAK1 & JAK2 inhibitor and has received the US FDA’s FTD for AA. The company plans to initiate a P-III study in Q4’20
Date: Jul 14, 2020
Product: Mosunetuzumab
- The US FDA has granted BTD to the Roche’s mosunetuzumab for the treatment of adult patients with r/r FL, prior treated with at least two systemic therapies
- The BT designation is based on P-I/Ib GO29781 study assessing mosunetuzumab in R/R non-Hodgkin lymphoma. The safety profile of the therapy was consistent with its mechanism of action
- Mosunetuzumab is an investigational CD20xCD3 T-cell engaging bispecific that targets CD20 on the surface of B-cells and CD3 on the surface of T-cells, being evaluated in clinical development program across several lymphoma indications both as monothx. and combination therapy
Date: Jul 23, 2020
Product: Mavacamten
- The US FDA has granted BTD to mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM)
- In May’2021, MyoKardia reported the results of the P-III EXPLORER study that demonstrated the robust treatment effect, with patient responses to treatment, including reductions in symptoms, improvements in cardiac function and reduction or elimination of the obstruction of the left ventricle and was well tolerated
- MyoKardia is currently preparing an NDA for mavacamten, with plans to submit to the FDA in Q1’21
Date: Jul 29, 2020
Product: MK-6482
- The designation is based on P-II study evaluating MK-6482 in patients with VHL-associated RCC with nonmetastatic RCC tumors >3cms in size, unless immediate surgery is required
- The FDA’s BT designation is granted to expedite the development and review of medicines that are intended to treat serious or life-threatening conditions and have demonstrated preliminary clinical evidence indicating that the medicine may provide a substantial improvement over available therapy on at least one clinically significant endpoint
- MK-6482 (formerly PT2977) is an investigational oral HIF-2α inhibitor, currently being evaluated in a P-III trial in advanced RCC (NCT04195750), a P-II trial in VHL-associated RCC (NCT03401788), and a P-I/II dose-escalation and dose-expansion trial in advanced solid tumors, including advanced RCC (NCT02974738)
Date: Jul 30, 2020
Product: Tagrisso (osimertinib)
- The BT designation is based on P-III ADAURA trial which involves assessing Tagrisso (80 mg) vs PBO in 682 patients with Stage IB, II, IIIA EGFRm NSCLC following complete tumor resection and adjuvant chemotherapy as indicated across 20 centers and 200+ countries including the US, EU, South America, Asia, and the Middle East
- The study resulted in improvement in DFS, reduction in risk of disease recurrence, or death by 79% in the adjuvant treatment of Stage IB-IIIA EGFRm NSCLC patients, also presented at ASCO 2020. Additionally, the trial will continue to assess OS
- Tagrisso (osimertinib) is third-generation, irreversible EGFR-TKI once-daily oral tablets approved 1st-line EGFRm advanced NSCLC and EGFR T790M mutation-positive advanced NSCLC in the US, Japan, China, the EU
Date: Jul 31, 2020
Product: Pevonedistat
- The BT designation is based on the final analysis of the Pevonedistat-2001 P-II study assessing pevonedistat + azacitidine vs azacitidine as monothx. in patients with rare leukemias, including HR-MDS
- The 1EPs of the study include OS, EFS, CR and transfusion independence, and AE profile. The designation addresses the needs of people living with HR-MDS, for whom few therapies exist, and the benefits are limited
- Pevonedistat is a first in class NEDD8-activating enzyme (NAE) inhibitor. The pre-clinical studies demonstrated the inhibition of NAE, blocked the modification of select proteins, which resulted in the disruption of cell cycle progression and cell survival, leading to cancer cell death
Date: Sep 08, 2020
Product: Plinabulin
- The designation is based on P-III PROTECTIVE-2 evaluating Plinabulin + Neulasta vs Neulasta alone for the treatment of CIN
- In the protocol-specified interim analysis, combination regimen was better than Neulasta alone in achieving the 1EPs with p<0.01 and have a well-tolerated safety profile with fewer Grade 4 AEs
- The company plans to report full results of the P-III PROTECTIVE-2 study in Q4’20 and file an NDA with the FDA by the end of 2020. The company has submitted an NDA to the NMPA on a rolling basis in Q1’20
Date: Sept 10, 2020
Product: Toripalimab
- The US FDA has granted the BTD for Toripalimab to treat nasopharyngeal carcinoma. The BTD will allow the company to work with the FDA to bring the therapy to patients worldwide expeditiously
- The US FDA’s BTD for the therapy supports and accelerate the commercial development plan of Toripalimab in the US
- Toripalimab is the 1st anti-PD-1 Ab to receive the BTD in China, it marks another regulatory milestone after FDA granted ODD in May’2020
Date: Sept 14, 2020
Product: Dupixent
- The BT designation is based on Part A of P-III study assessing Dupixent (300mg) in 81 patients aged ≥12yrs. with EoE for 24wks.
- The Part A of P-III study met its co-1EPs and 2EPs i.e. reduction in symptoms, esophageal inflammation, abnormal endoscopic findings in the esophagus and has demonstrated safety results consistent with the known safety profile of Dupixent in its approved indications
- The P-III study is ongoing with additional patients enrolling in Part B as well as patients continuing in a 28wks. extended active treatment period (Part C) after completing either Part A or B. Dupixent is the first and only biologic to show positive P-III results in patients aged ≥12yrs. with EoE and has received the US FDA’s ODD in 2017
Date: Sept 16, 2020
Product: Magrolimab
- The BT designation is based on part B of the P-I study assessing Magrolimab + Azacitidine in 33 previously untreated intermediate, high, and very high-risk MDS patients. The results are presented at the 2020 European Hematology Society Congress
- The part B of the P-I study showed positive results with 91% achieving OR and 42% achieving CR and the combination was generally well-tolerated
- Magrolimab is anti-CD47 mAb, currently being studied P-III ENHANCE trial in previously untreated higher MDS risk evaluating the safety and efficacy of dual regimen, as measured by CR and duration of CR. The therapy has received the US FDA’s FT designation for MDS, AML, DLBCL, and FL and the FDA’s ODD for MDS & AML along with EMA’s ODD for AML
Date: Sep 25, 2020
Product: Disitamab Vedotin (RC48)
- The US FDA has granted BTD for disitamab vedotin (RC48) for 2L treatment patients with HER2+ LA/m-UC who had prior received Pt-containing CT treatment
- Earlier, RemeGen reported the FDA’s clearance of an IND application for a P-II clinical study in the US and the grant of FTD for disitamab vedotin
- RC48 is a novel humanized anti-HER2 ADC, currently being studied in multiple late-stage clinical trials across solid tumor types
Date: Oct 05, 2020
Product: Farxiga
- The BT destination follows P-lll DAPA-CKD assessing Farxiga (10mg, qd) + SOC vs PBO in 4,304 patients with CKD Stages 2-4 and elevated urinary albumin excretion, with/ out T2D across 21 countries
- Results: 39% reduction in the composite measure of worsening of renal function or risk of CV or renal death; 31% reduction in death from any cause
- Farxiga (PO, qd) is an SGLT2 inhibitor indicated in adults for the treatment of insufficiently controlled T2D as both monothx. and combination therapy as an adjunct to diet and exercise to improve glycemic control, weight loss, and BP reduction
Date: Oct 05, 2020
Product: IMGN632
- The US FDA has granted BTD for IMGN632 to treat relapsed or refractory BPDCN
- The BTD was based on findings from the BPDCN cohort of the first-in-human study of IMGN632, for which initial data were presented in ASH 2019. Updated data from the IMGN632 monothx. BPDCN dose expansion cohort will be presented at ASH in Dec’2021
- MGN632 is a CD123-targeting ADC and is currently evaluated in multiple cohorts, including monothx. for patients with BPDCN and MRD+ AML following frontline induction therapy and in combinations with Vidaza (azacitidine) and Venclexta (venetoclax) for patients with relapsed/refractory AML
Inventiva’s Lanifibranor Received the US FDA’s Breakthrough Designation for the Treatment of NASH
Date: Oct 12, 2020
Product: Lanifibranor
- The designation is based on the P-IIb NATIVE trial involves assessing lanifibranor vs PBO in patients with NASH for 24wks. Lanifibranor is the first drug candidate to be granted BTD in NASH since 2015
- The study met its 1EPs i.e. demonstrated significant reduction of SAF and 2EPs, including NASH resolution with no worsening of fibrosis, improvement of liver fibrosis with no worsening of NASH in both ITT and PP populations
- The company expected to hold the end of the P-IIb NATIVE trial meeting with the FDA and to receive regulatory feedback from the EMA in Q4’20. The designation supports the decision to initiate the P-III trial of lanifibranor in H1’21
F2G Received the US FDA’s Breakthrough Therapy Designation for Olorofim
Date: Oct 22, 2020
Product: Olorofim
- The US FDA has granted BTD to Olorofim for the treatment of CNS Valley Fever (coccidioidomycosis)
- The therapy is currently being evaluated in P-IIb study in patients with coccidioidomycosis with proven IFD or probable IA and either refractory disease, resistance, or intolerance to available agents
- The BTD follows the previous BTD that was granted on Nov 11, 2019, for the treatment of invasive mold infections in patients with limited or no treatment options, including aspergillosis refractory or intolerant to currently available therapy, and infections due to Lomentospora prolificans, Scedosporium, and Scopulariopsis species
Date: Nov 16, 2020
Product: Vixarelimab
- The BTD is based on P-IIa assessing vixarelimab in reducing pruritus in patients with prurigo nodularis
- The study met its 1EPs i.e reduction in WI-NRS from baseline @8wks. in vixarelimab recipients and patients also received PN-IGA score of 0/1 @8wks.
- Kiniksa expects to initiate a P-IIb clinical trial of vixarelimab in prurigo nodularis, evaluating a range of once-monthly dose regimens, by the end of 2021. Vixarelimab is a fully-human mAb that targets oncostatin M receptor beta (OSMRβ)
ViiV Healthcare’s Cabotegravir Received US FDA’s Breakthrough Therapy Designation for HIV Prevention
Date: Nov 18, 2020
Product: Cabotegravir
- The BT designation is based on P-IIb/III HPTN 083 study assessing cabotegravir (q8w) vs. FTC/TDF tablets (qd PO, 200/300 mg) in a study population of 4,566 for HIV prevention. The data were presented at the 23rd International AIDS Conference (AIDS 2020)
- Results: HPTN 083 study showed that cabotegravir was 66% more effective at preventing HIV compared to daily oral FTC/TDF tablets. The HIV incidence rate is 0.41% in the cabotegravir group and 1.22% in the FTC/TDF group
- A partner HIV prevention study (HPTN 084) in sub-Saharan African women was stopped earlier this month based upon the recommendation of the independent DSMB following the superiority of cabotegravir to oral FTC/TDF tablets. The company plans to use the data from both the HPTN studies for future regulatory submissions
Date: Nov 24, 2020
Product: D-PLEX₁₀₀
- The BTD is based on a P-II trial evaluating D-PLEX100 vs SOC alone in 201 patients for the prevention of SSIs in abdominal colorectal surgery
- The results demonstrated a significant decrease in SSIs of 59 % in the ITT population and a decrease of 69% in the Per Protocol population
- The ongoing P-III studies in abdominal surgery, SHIELD I and SHIELD II are on track. D-PLEX100 has received two FDA’s FTD for the prevention of post-abdominal surgery incisional infections and for the prevention of sternal wound infections post-cardiac surgery, as well as two QIDP’s in the same indications
Date: Nov 30, 2020
Product: Zanidatama
- The US FDA has granted the BTD for zanidatamab in patients with previously-treated HER2 gene-amplified BTC
- The designation was based on a P-I trial assessing zanidatamab in patients with BTC. The company has initiated a P-II study, which is designed to support accelerated approval based on 1EPs of ORR, and 2EPs of DoR and safety
- Zanidatamab will now be eligible for accelerated approval, PR and rolling review as well as intensive FDA guidance on an efficient drug development program. The company plans to submit BLA as early as 2022
Date: Dec 08, 2020
Product: Repotrectinib
- The US FDA has been granted BTD for the treatment of patients with ROS1+ metastatic NSCLC who have not been treated with ROS1 TKI-naïve
- The designation is based on P-I & P-II portion of TRIDENT-1 study of repotrectinib in TKI-naïve ROS1-positive NSCLC patients. The study is currently evaluating patients in multiple potentially registrational cohorts
- The company plans to report updated P-II TRIDENT-1 study results in patients with TKI-naive ROS1-positive NSCLC at the World Conference on Lung Cancer on Jan 31, 2021
Date: Dec 09, 2020
Product: Sotorasib
- The BT designation is based on P-II CodeBreaK 100 study assessing Sotorasib in patients with advanced NSCLC with KRAS G12C mutation whose cancer had progressed despite prior treatment with CT and/or immunotherapy
- The company is currently recruiting in a P-III study (CodeBreaK 200) assessing sotorasib vs docetaxel in patients with KRAS G12C-mutated NSCLC. Amgen has several P-Ib combination studies across various advanced solid tumors (CodeBreaK 101) open for enrollment
- Sotorasib has also accepted into FDA’s Real-Time Oncology Review Pilot Program. Additionally, the company plans to submit the NDA to the US FDA by the end of 2020
Date: Dec 14, 2020
Product: AVB-620 (pegloprastide)
- The US FDA has granted BTD to pegloprastide (AVB-620) for the intraoperative detection and visualization of positive margins during breast cancer surgery
- Earlier, the company reported results of P-II/III study that demonstrated the use of pegloprastide during surgery correctly identified cancer in ~ 75% of patients who would have otherwise been candidates for a repeat (re-excision) surgery
- Pegloprastide is designed to deliver a fluorescent marker to cancer cells to aid surgeons in identifying positive margins in real-time during surgery
Date: Dec 15, 2020
Product: IO102 + IO103
- The BTD is based on P-I/II MM1636 study assessing IO102-IO103 (q2w, until 12wks. and thereafter q4w up to 1yr.) in combination with anti-PD-1 Ab, as a 1L treatment for metastatic melanoma
- The combination of IO102 and IO103 vaccines and nivolumab demonstrated encouraging early efficacy data; ORR (79%) was reached with CR (45%) or complete disappearance of their tumors
- IO102 and IO103 are first-in-class, immune modulatory vaccines designed to engage and activate IDO and PD-L1 specific human T-cells
Date: Dec 15, 2020
Product: CUTX-101
- The US FDA has granted BTD to CUTX-101 for the potential treatment of Menkes disease
- The FDA has previously ODD, FTD and RPDD to CUTX-101 for the treatment of Menkes disease. Additionally, the EMA has previously granted ODD to CUTX-101
- The rolling submission of NDA to the US FDA for CUTX-101 is expected to be initiated in Q1’21 and to be completed by the end of the Q2’21
Date: Dec 16, 2020
Product: Iptacopan
- The US FDA has granted BTD in paroxysmal nocturnal hemoglobinuria and RPDD in C3 glomerulopathy
- The BTD is based on results from two ongoing P-II studies, where iptacopan showed benefits both in patients who remained anemic and dependent on transfusions despite SOC anti-complement treatment as well as monothx. in anti-C5 naïve PNH patients
- Iptacopan is a first-in-class, orally administered, potent and highly selective factor B inhibitor of the alternative complement pathway with its first FDA filing anticipated in 2023
Related Post: Insights+: Breakthrough Therapy Designation by the US FDA in 2019
The post Insights+: Breakthrough Therapy Designation by the US FDA in 2020 first appeared on PharmaShots.
